[1]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268-272.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
　Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):268-272.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
点击复制

镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第3期
页码:
268-272
栏目:
出版日期:
2015-05-25

文章信息/Info

Title:
Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases
作者:
桂继琮;  刘兴党
复旦大学附属华山医院核医学科, 上海, 200040
Author(s):
Gui Jicong;  Liu Xingdang
Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
关键词:
镭; 氯化物; 前列腺肿瘤; 肿瘤转移
Keywords:
Radium; Chlorides; Prostatic Neoplasms; Neoplasms metastasis
DOI:
10.3760/cma.j.issn.1673-4114.2015.03.018
摘要:
近年来,全世界前列腺癌的发病率和病死率不断增长,各种治疗方法的研究也进展迅速。镭-223发射的重α粒子(具有<100μm的超短波)靶向作用于骨转移部位和周围新骨生长区域。镭-223氯化物在药物临床试验中以稳定的安全性显著降低了患者的病死率,成为近来被寄予厚望的转移性去势抵抗性前列腺癌(CRPC)治疗领域的"主角"。2013年美国食品药品管理局已批准镭-223氯化物用于治疗有症状的骨转移、未发现内脏转移的CRPC患者。未来其联合治疗方案将会是研究的重点。
Abstract:
Prostate carcinoma rates and mortalities are increasing worldwide.The therapeutic landscape of castration-resistant prostate carcinoma (CRPC) has changed rapidly.Radium-223 chloride, which is a radiopharmaceutical agent,targets bone metastasis by emitting high-energy alpha-particles with extremely short range (<100μm).This chemical is effective in reducing mortality without increasing toxicity.Thus,this agent has the potential to become a new alternative for treating patients with CRPC.The Food and Drug Administration approved radium-223 dichloride for treating patients with CRPC, symptomatic bone metastases,and unknown visceral metastatic disease in 2013.Therefore,combination and sequencing strategies will be future research directions.

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Can-cer J Clin, 2015, 65(1):5-29.
[2] 韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013, 18(4):330-334.
[3] 赫捷, 陈万青. 2012中国肿瘤登记年报[M]. 北京:军事医学科学出版社, 2012.
[4] Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6):1079-1092.
[5] Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant Prostate Cancer:From New Pathophysiology to New Treatment Targets[J]. Eur Urol, 2009, 56(4):594-605.
[6] Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1:screening, diagnosis, and treatment of clin-ically localised disease[J]. Eur Urol, 2011, 59(1):61-71.
[7] Chin JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatec-tomy in prostate cancer management:evidentiary base[J]. Can Urol Assoc J, 2010, 4(1):13-25.
[8] Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet No. 22(abridged):radiobiology and dosimetry of alpha-Particle emitters for targeted radionuclide therapy[J]. J Nucl Med, 2010, 51(2):311-328.
[9] Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radio-pharmaceuticals for treatment of osseous metastases, Part 1:α therapy with 223Ra-dichloride[J]. J Nucl Med, 2014, 55(2):268-274.
[10] Henriksen G, Breist?l K, Bruland ?S, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrat-ed in an experimental skeletal metastases model[J]. Cancer Res, 2002, 62(11):3120-3125.
[11] Hobbs RF, Song H, Watchman CJ, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy[J]. Phys Med Biol, 2012, 57(10):3207-3222.
[12] Neuman WF, Hursh JB, Boyd J, et al. On the mechanism of skeletal fixation of radium[J]. Ann N Y Acad Sci, 1955, 62(6):125-136.
[13] Parker C, Heinrich D, O’sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer(CRPC):a phase Ⅲ randomized trial(ALSYMPCA)[Ab-stract 1LBA][J]. Eur J Cancer, 2011, 47(suppl 2):3.
[14] Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection:U. S. food and Drug Administration drug approval sum-mary[J]. Clin Cancer Res, 2014, 20(1):9-14.
[15] Nilsson S, Larsen RH, Foss?SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metas-tases[J]. Clin Cancer Res, 2005, 11(12):4451-4459.
[16] Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:a randomised, multicentre, placebo-controlled phase Ⅱ study[J]. Lancet Oncol, 2007, 8(7):587-594.
[17] Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-re-sponse, multicenter phase Ⅱ study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-re-sistant prostate cancer[J]. Eur J Cancer, 2012, 48(5):678-686.
[18] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3):213-223.
[19] Dauer LT, Williamson MJ, Humm J, et al. Radiation safety consid-erations for the use of 223RaCl DE in men with castration-resistant prostate cancer[J]. Health Phys, 2014, 106(4):494-504.
[20] Coleman R, Aksnes AK, Naume B, et al. A phase Ⅱa, nonrandom-ized study of radium-223 dichloride in advanced breast cancer pa-tients with bone-dominant disease[J]. Breast Cancer Res Treat, 2014, 145(2):411-418.
[21] Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-tar-geted alpha particle therapy for hormone-refractory breast cancer metastatic to bone[J]. Exp Hematol Oncol, 2014, 3:23.
[22] Algeta ASA. A study of Alpharadin with docetaxel in patients with bone metastasis from castration-resistant prostate cancer (CRPC)[DB/OL]. US National Institutes of Health, ClinicalTrials. gov, 2012[2015-01-12].http://www.clinicaltrials.gov/ct2/show/NCT01106352.
[23] Clark MJ, Harris N, Griebsch I, et al. Patient-reported outcome la-beling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and Euro-pean Union[J]. Health Qual Life Outcomes, 2014, 12:104.
[24] Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metas-tasis-free survival in men with castration-resistant prostate cancer:results of a phase 3, randomised, placebo-controlled trial[J]. Lancet, 2012, 379(9810):39-46.
[25] Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J]. Clin Cancer Res, 2011, 17(11):3520-3526.

备注/Memo

备注/Memo:
收稿日期:2015-01-12。
通讯作者:刘兴党,Email:xingdliu@yahoo.com
更新日期/Last Update: 1900-01-01